Tardive Dyskinesia

Tardive Dyskinesia (TD) is a movement disorder resulting from prolonged use of certain medications, often with psychiatric implications. The Journal of Clinical Psychiatry offers comprehensive insights into TD, from its pathophysiology to management strategies. Our expert editors ensure that the content is both clinically relevant and actionable, aiding psychiatrists in diagnosing, preventing, and treating this challenging condition.

Recently published articles about Tardive Dyskinesia

Weekly Mind Reader: Phentermine-Related Tardive Dyskinesia
news

June 28, 2024

This week features a rare report of phentermine-induced tardive dyskinesia, research on suicide neural markers, and maternal mental health.
JCP
The Clinician’s Tardive Inventory
Original Research

January 24, 2024

Accurately identifying the severity and functional impact of tardive dyskinesia is essential. This report describes a new instrument, the Clinician’s Tardive Inventory, which aims to address shortcomings of existing...
Richard M. Trosch, Cynthia L. Comella, Stanley N. Caroff, et al
How Tardive Dyskinesia Impacts Patients Using Antipsychotics
news

August 22, 2023

An expert explains the mechanism, risk factors, progression, and quality of life implications of Tardive Dyskinesia.
A Reason for Hope in Rett Syndrome: New Medications, Novel Gene Therapies
news

May 3, 2023

Some emerging therapies and treatment options hold promise in Rett Syndrome, a rare neurodevelopmental disorder that primarily affects girls.
New Scale Measures True Impact of Tardive Dyskinesia
news

April 13, 2023

A panel of experts has developed an easy-to-use scale to assess the symptoms and challenges of having tardive dyskinesia.
JCP
Impact of Tardive Dyskinesia on Patient Lives
Original Research

April 3, 2023

This survey reveals the substantial burden of tardive dyskinesia on people’s lives and on the management of their underlying condition.
Rakesh Jain, Rajeev Ayyagari, Debbie Goldschmidt, et al

Recent JCP Articles on Tardive Dyskinesia

JCP
Webcast

March 9, 2021

In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia, how to observe patients (whether in person or via telemedicine), and how to educate patients and families...
Joseph P. McEvoy, Andrew A. Nierenberg
JCP
Educational Activity

December 1, 2020

Although clinicians are pressed for time, diligence in assessing for tardive dyskinesia in patients taking antipsychotics is crucial, especially now that treatment is available. In this brief CME activity,...
Andrew A. Nierenberg
JCP
DELETE eReport

November 3, 2020

Measurement-based care (MBC) has been found to be effective in patients with psychiatric conditions. In this CME activity, learn how Dr Joseph McEvoy employs MBC for patients with tardive...
Joseph P. McEvoy

Recent PCC Articles on Tardive Dyskinesia

PCC
Case Report

February 18, 2021

In this report, the authors describe the successful management of tardive dyskinesia with quetiapine in a man with schizoaffective disorder and comorbid diabetes with renal and neurologic complications as...
Shayanth Manche Gowda, S. Madhupreetha, Vijay Kumar KG
PCC
Letter to the Editor

January 10, 2019

Your patient runs out of his antidepressant and a week later his mouth hurts. At presentation, you realize it's because his mouth is constantly twitching and he's been biting...
Lu Wu, Ethan A. Gerdts, Al Alam
PCC
Letter to the Editor

April 12, 2018

Vitamin E is one of many antioxidants used for the treatment of tardive dyskinesia. It has been suggested that long-term vitamin E therapy may increase risk for prostate cancer,...
O. Greg Deardorff, Nicole A. Burns, David R. Hunter

Featured Tardive Dyskinesia Research

JCP
DELETE eReport

September 29, 2020

Read an article on how to reduce Tardive dyskinesia (TD) symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
Joseph P. McEvoy
JCP
Educational Activity

December 24, 2019

What steps do you take when patients exhibit tardive dyskinesia? Are you familiar with treatment guidelines and data on approved and non-approved strategies? Explore recommendations from Dr Daniel Kremens.
Daniel E. Kremens
JCP
Educational Activity

December 17, 2019

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
Joseph P. McEvoy
JCP
Impact-TD Scale: A Clinical Tool to Assess the Impact of Tardive Dyskinesia
Consensus Statement

November 28, 2022

This easy-to-use scale developed by 7 experts measures the impact of TD on patients’ daily functioning.
Richard Jackson, Matthew N. Brams, Noelle E. Carlozzi, et al
JCP
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics
Original Research

August 3, 2022

This study compared spontaneous reporting of tardive dyskinesia with long-acting injectable versus oral antipsychotics.
Fuminari Misawa, Yasuo Fujii, Hiroyoshi Takeuchi
PCC
Tardive Dyskinesia in a Community Mental Health Center
Original Research

June 28, 2022

This study examined clinician documentation of tardive dyskinesia in a large electronic medical record database from a single large community mental health treatment center.
Carol S. North, Katy McDonald, Judith Hunter, et al
JCP
DELETE eReport

October 12, 2021

Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications...
Christoph U. Correll, Leslie Citrome
JCP
Academic Highlights

August 31, 2021

Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
Christoph U. Correll, Leslie Citrome
PCC
Systematic Review

May 6, 2021

ECT may be a successful treatment for some cases of tardive dyskinesia. In this review, the authors accumulate all the recent evidence for the efficacy of ECT in treating...
Ahmed Saeed Yahya, Shakil Khawaja

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe